## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Emma R. Parmee, et al.

Serial No.

10/537,187

Filed:

June 2, 2005

For: SPIROCYCLIC UREAS, COMPOSITIONS

CONTAINING SUCH COMPOUNDS AND METHODS

OF USE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Art Unit: To Be Assigned

Examiner:

To Be Assigned

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

## INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

PE	RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE	
ALIG 28 TRUSH BY			
22.05.16			

If this is inconvenient, additional copies will be submitted upon request. 6. In accordance with 37 C.F.R. 1.97, (check one) the attached information is filed within three months of the filing date of the captioned case. the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits. the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114. the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p). each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement. no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Richard C. Billups

Attorney For Applicant(s)

Reg. No. 31,916 MERCK & CO., INC. Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4683

Date: 8/25/

Su	Substitute for form 1449A/PTO			COMPLETE IF KNOWN		
I	NFORMATION	N DIS	CLOSURE	Application Number	10/537,187	
<u> </u>	OF A OFFINATION ID	37 A D	DI ICANOFE	Filing Date	June 2, 2005	
5	TATEMENT B	Y AP	PLICANI - 4	First Named Inventor	Emma R. Parmee, et al.	
			ecessary) 2 8 2006	Group Art Unit	To Be Assigned	
	(use as many shee	ets as n	ecessary)	Examiner Name	To Be Assigned	
Sheet	1	of	Closes	Attorney Docket Number	21208P	

		U.S. I	PATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document  Kind Number Code (if know	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	US 5,776,954	de Laszlo et al	07/07/1998
	2	US 6,218,431 B1 Equivalent to	Schoen et al	04/17/2001
		WO 98/04528		
	3	US 6,562,807 B2 Equivalent to	Jorgensen et al	05/13/2003
-		WO 02/00612		
	4	US 6,613,942 B1 Equivalent to	Ling et al	09/02/2003
		WO 99/01423		
	5	US 6,503,949 B1 Equivalent to	Lau et al	01/07/2003
		WO 69810		
			·	
-				

			FOREI	GN PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Patent Documen Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	PCT	WO 97/16442		Merck & Co., Inc	05/09/1997
	2	PCT	WO 98/21957		Merck & Co., Inc	05/28/1998
	3	PCT	WO 98/22108		Merck & Co., Inc	05/28/1998
	4	PCT	WO 98/22109		Merck & Co., Inc	05/28/1998
	5	PCT	WO 99/05117		LG Chemical Ltd.	02/04/1999
	6	PCT	WO 99/32448		Amgen Inc	07/01/1999
	7	PCT	WO 00/39088		Novo Nordisk A/S	07/06/2000
	8	PCT	WO 02/40444 A1		Novo Nordisk	05/23/2002
		ļ				
L		<u> </u>			<u> </u>	

Examine	r
Signature	•